Tag: FDA

FDA: Class I recall of certain ICU Medical infusion system batteries

Editor's Note The Food and Drug Administration (FDA), on May 22, identified the recall by ICU Medical of replacement batteries for its Plum 360, Plum A+, and Plum A+3 infusions systems as Class I, the most serious. The recall was initiated because a manufacturing defect substantially diminished how long the…

Read More

By: Judy Mathias
May 23, 2023
Share

FDA finalizes recommendations for blood donations

Editor's Note The Food and Drug Administration (FDA), on May 11, finalized its recommendations for assessing blood donor eligibility, which uses individual risk-based questions to reduce the risk of transmitting HIV. The questions will be the same for all donors, regardless of sexual orientation, sex, or gender. The new policy…

Read More

By: Judy Mathias
May 22, 2023
Share

XBB.1.16 grows to 14% of US COVID-19 cases

Editor's Note Estimates from the Centers for Disease Control and Prevention find the emerging COVID-19 Omicron subvariant XBB.1.16, dubbed Arcturus, is responsible for more than 14% of COVID-19 cases in the US over the past 2 weeks, up from nearly 7% in the prior 2 weeks, according to the May…

Read More

By: Judy Mathias
May 15, 2023
Share

FDA updates Safety Communication on Halyard surgical N95 respirators

Editor's Note In response to questions, on April 21, the Food and Drug Administration (FDA) provided an update to its Safety Communication that enables the use of existing inventory of the O&M Halyard FLUIDSHIELD Surgical N95 Respirator Masks, Orange (Regular), Level 3, (Model 46727). The FDA recommends that, if necessary,…

Read More

By: Judy Mathias
April 25, 2023
Share

FDA: Class I recall of Ivenix Infusion System

Editor's Note The Food and Drug Administration (FDA), on April 19, identified the recall by Fresenius Kabi USA of its Ivenix Infusion System as Class I, the most serious. The recall was initiated because of a leak in the system that allows fluid to enter the administration set loading area…

Read More

By: Judy Mathias
April 19, 2023
Share

FDA updates opioid prescribing information

Editor's Note The Food and Drug Administration (FDA), on April 13, updated prescribing information for all opioid pain medications, including requiring all packaging to have updated labeling and safety information. This includes stating that: for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medications, the risk of overdose…

Read More

By: Judy Mathias
April 18, 2023
Share

FDA: Class I recall of Abbott’s glucose monitoring systems

Editor's Note The Food and Drug Administration (FDA), on April 6, identified the recall by Abbott of its FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems as Class I, the most serious. The recall was initiated because the systems’ reader devices, which use rechargeable…

Read More

By: Judy Mathias
April 11, 2023
Share

FDA: Class I recall of certain Philips Respironics reworked DreamStation CPAP, BiPAP machines

Editor's Note The Food and Drug Administration, on April 7, identified the recall by Philips Respironics of certain reworked DreamStation continuous positive airway pressure (CPAP) and bileveled positive airway pressure (BiPAP) machines as Class I, the most serious. These machines also were recalled in June 2021. The recall was initiated…

Read More

By: Judy Mathias
April 10, 2023
Share

CDC: One bivalent COVID-19 booster is sufficient for now

Editor's Note The Centers for Disease Control and Prevention (CDC), on March 29, updated its COVID-19 vaccination guidelines to say that one dose of the bivalent booster is all that is recommended at this time, even for those who were last vaccinated more than 6 months ago. The CDC notes…

Read More

By: Judy Mathias
March 30, 2023
Share

Impact of expectations, prior experiences on adverse effect reports after COVID-19 vaccinations

Editor's Note This German study finds that expectations and prior experiences were associated with increased adverse effect reports in individuals receiving their second COVID-19 vaccinations. Researchers collected data from 1,678 individuals receiving Pfizer BioNTech and Moderna mRNA vaccines. Severe adverse effect reports were higher in those: expecting a lower benefit…

Read More

By: Judy Mathias
March 27, 2023
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat